Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Osteopore Ltd. ( (AU:OSX) ).
Osteopore Limited has applied to the ASX for quotation of 50,000,000 new ordinary fully paid shares, with an issue date of 5 March 2026, under a standard Appendix 2A application. The move significantly increases the number of quoted securities on issue, indicating a substantial equity event that may affect the company’s capital structure, liquidity, and ownership base once the new shares commence trading.
The application confirms the securities result from the exercise or conversion of options or other convertible instruments, formalising their transition into quoted ordinary shares. This capital markets activity underscores Osteopore’s ongoing use of equity-linked instruments to fund operations or strategic initiatives, and it may influence valuation dynamics and dilution considerations for existing shareholders.
The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is a medical technology company listed on the ASX under the code OSX. The company operates in the healthcare sector, focusing on products that require regulatory oversight and capital market access, and raises funds via equity issuance to support its business activities and growth initiatives.
Average Trading Volume: 31,878,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.86M
See more insights into OSX stock on TipRanks’ Stock Analysis page.